NCT02177123已完成不适用
Post Market Study to Evaluate Safety and Effectiveness of the InnFocus Microshunt™ (MIDI Arrow) in Patients With Primary Open Angle Glaucoma
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 107
- 试验地点
- 12
- 主要终点
- Number of Participants With Study Success
研究概览
简要总结
Prospective, multicentric, single arm post market study to gather safety and effectiveness data on the CE Marked InnFocus MicroShunt (MIDI Arrow) device in primary open angle glaucoma patients
详细描述
The purpose of this study is to collect additional safety and effectiveness data on the InnFocus MicroShunt (MIDI Arrow) in subjects suffering from primary open angle glaucoma who are inadequately controlled on maximum tolerated medical therapy with intraocular pressure ≥ 18 mm Hg and ≤ 35 mm Hg and/or where glaucoma progression warrants surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has mild to moderate primary open glaucoma where the intraocular pressure is not adequately controlled on maximum tolerated medical therapy and has intraocular pressure greater than or equal to 18mmHg and less than or equal to 35mmHg while on glaucoma medications and/or where glaucoma progression warrants surgery.
- •Primary open angle glaucoma diagnosis based on glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities documented on slit lamp stereo biomicroscopy or in stereo disc photos:
- •Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially at the inferior or superior poles.
- •Localized abnormalities of the peripapillary retinal nerve fiber layer, especially at the inferior or superior poles.
- •Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue.
- •Disc rim or peripapillary retinal nerve fiber layer hemorrhages.
- •Subject willing to comply with study requirements. 5) Subject who has signed an approved informed consent form
排除标准
- •Active iris neovascularization, active proliferative retinopathy or other ophthalmic disease that could confound study results.
- •Iridocorneal endothelial syndrome.
- •Epithelial or fibrous downgrowth.
- •Secondary glaucoma such as post-trauma, pseudo-exfoliative, etc.
- •Chronic ocular inflammatory disease.
- •Prior argon laser, selective laser, or micropulse trabeculoplasty within 90 days of enrollment.
- •Inability to obtain accurate IOP measurement throughout the study. For example: a history of corneal surgery, corneal opacities or disease/pathology (Active corneal infection or Fuchs dystrophy are examples.).
- •Severe anterior or posterior blepharitis.
- •Previous incisional ophthalmic surgery, excluding uncomplicated clear corneal phacoemulsification (cataract) surgery at least 6 months prior to enrollment.
- •Prior laser peripheral iridotomy.
- •Fellow eye with poorer than 20/200 best-corrected visual acuity (BCVA)
- •Angle closure glaucoma or narrow anatomical chamber angle as identified by gonioscopy and classified as Shaffer Grade 0 or
- •Previous cyclodestructive procedure.
- •Use of oral hypotensive glaucoma medications for treatment of the fellow eye.
- •Severe anterior or posterior blepharitis.
- •Unwilling to discontinue contact lens use after surgery.
- •Previous incisional ophthalmic surgery, excluding uncomplicated clear corneal phacoemulsification (cataract) surgery at least 6 months prior to enrollment.
- •Presence of an anterior chamber IOL (AC-IOL).
- •Prior laser peripheral iridotomy.
- •Need for glaucoma surgery combined with other ocular procedures or anticipated need for additional ocular surgery during the investigational period.
- •Fellow eye with poorer than 20/200 best-corrected visual acuity (BCVA)
- •Known allergy or other contraindication to Mitomycin C (MMC) drug.
- •Angle closure glaucoma or narrow anatomical chamber angle as identified by gonioscopy and classified as Shaffer Grade 0 or
- •Any condition that prevents the investigational device implantation or trabeculectomy in the superior region of the study eye (e.g., peripheral anterior synechiae, scleral staphyloma or conjunctival scarring).
- •Diagnosed degenerative visual disorders not associated with existing glaucoma condition (e.g., advanced dry or wet macular degeneration or other retinal disorders, central retinal artery or vein occlusion) or choroidopathy (e.g., choroidal detachment, effusion, choroiditis, or neovascularization).
- •Central corneal thickness that is less than 450 microns or greater than 620 microns.
- •Previous cyclodestructive procedure.
- •Prior retinal laser procedure conducted for any purpose other than treatment of retinal tear or hole.
- •Conditions associated with elevated episcleral venous pressure such as active thyroid orbitopathy, cavernous sinus fistula, Sturge-Weber syndrome, orbital tumors, orbital congestive disease.
- •Clinically significant sequelae from trauma (e.g., chemical burns, blunt trauma, etc.)
- •Ocular pathology or medical condition for which, in the investigator's judgment, the following factors would either place the subject at increased risk of complications or contraindicate device implantation or interfere with compliance to elements of the study protocol (e.g., ophthalmic examinations, follow-up visits),
- •inability to reliably complete visual field testing over the course of the study,
- •uncontrolled systemic disease (e.g. diabetes, hypertension) that could compromise their participation in the study.
- •Disorders that pose a fall risk, as well as compromise ability to take a visual field exam and take glaucoma medications (e.g., Parkinson's disease),
- •inability to discontinue use of blood thinners within the surgeon's standard preoperative or postoperative instructions.
- •immunodeficiency concerns.
- •known corticosteroid responders whose pressure increases would not allow them to withstand the postop corticosteroid regimen.
- •Intraocular silicone oil.
- •Ocular steroid use in the planned study eye or systemic steroid use anytime within three months of the procedure. (This would not include the use of inhaled or dermatologic steroids.)
- •Chemotherapy within six months of the screening visit.
- •Use of oral hypotensive glaucoma medications for treatment of the fellow eye.
- •A requirement of general anesthesia for the procedure.
- •Bacterial conjunctivitis
- •Bacterial corneal ulcers
- •Endophthalmitis
- •Orbital cellulitis
- •Bacteremia or septicemia
- •Active scleritis
- •Severe dry eye syndrome
- •Severe myopia
- 另有 1 项未显示
结局指标
主要结局
Number of Participants With Study Success
时间窗: Month 6, 9, 12, and 24
Rate of success with respect to IOP at Months 6, 9, 12 and 24 on ITT population
次要结局
- IOP Change(Day 1, Day 7, Week 4, Month 3, Month 6, Month 9, Month 12, and Month 24)
研究者
研究点 (12)
Loading locations...
相似试验
已完成
不适用
Evaluate Safety and Efficacy of Pronavi Microcatheter for Use in Endovascular InterventionsPeripheral Arterial DiseaseCoronary Artery DiseaseNCT05747287BrosMed Medical Co., Ltd60
已完成
不适用
Evaluate Safety and Efficacy of Alveo HP Balloon Dilatation Catheter for Balloon Dilatation of Coronary Artery StenosisCoronary Artery DiseaseNCT05998252BrosMed Medical Co., Ltd60
已完成
不适用
Post Market Study Using the Xoft Axxent SystemBreast CancerNCT01017549Xoft, Inc.44
已完成
不适用
Prospective Clinical Evaluation of BD NRFit™ Devices and Accessories.AnesthesiaAnalgesiaNCT05953363Becton, Dickinson and Company161
招募中
不适用
ACOART BTK RENEW：A Post Market Clinical StudyPeripheral Artery DiseaseNCT04885985Acotec Scientific Co., Ltd107